BioMarin Announces Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $80 at Oppenheimer
October 24, 2019 7:02 AM EDTOppenheimer analyst Leland Gershell lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $80.00 (from $81.00) while maintaining a Perform rating.
The analyst commented, "BMRN's 3Q19 total product revenue of $451M was roughly in line with consensus of $448M, with lower R&D... More
BioMarin Pharma (BMRN) Tops Q3 Revenue
October 23, 2019 4:16 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.30, which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $461.1 million versus the consensus estimate of $454.55 million.
Commenting on third quarter results, Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, said, "BioMarin is entering a stage that I believe will bring significant growth as we get closer to submitting marketing applications for valoctocogene roxaparvovec for severe hemophilia A and a pivotal data read-out for vosoritide for children with achondroplasia. These potential new products, combined with our strong base business... More
